Hypertensive emergencies: An update

Current Opinion in Critical Care

Volumn 17, Issue 6, 2011, Pages 569-580

  Marik, Paul E ^a   Rivera, Racquel ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b SENTARA NORFOLK GENERAL HOSPITAL   (United States)

Author keywords

aortic dissection; clevidipine; eclampsia; esmolol; hypertension; hypertensive emergencies; labetalol; nicardipine; pulmonary edema

Indexed keywords

BENZODIAZEPINE; CLEVIDIPINE; CLONIDINE; CREATININE; DILTIAZEM; ELECTROLYTE; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; LACTATE DEHYDROGENASE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; VERAPAMIL;

ACUTE KIDNEY FAILURE; AORTA DISSECTION; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ECLAMPSIA; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEREDITY; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPOTENSION; INCIDENCE; KIDNEY INFARCTION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EDEMA; LUPUS VULGARIS; MEDICAL HISTORY; MICROANGIOPATHIC ANEMIA; MICROANGIOPATHY; MUSCLE TWITCH; PATHOPHYSIOLOGY; PHLEBITIS; PHYSICAL EXAMINATION; POSTOPERATIVE HYPERTENSION; PREECLAMPSIA; PREVALENCE; RECOMMENDED DRUG DOSE; REFLEX TACHYCARDIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEDATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TACHYPHYLAXIS; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CRITICAL CARE; CRITICAL ILLNESS; EMERGENCY MEDICAL SERVICES; HUMANS; HYPERTENSION; LABETALOL; NICARDIPINE; PREVALENCE; PROPANOLAMINES; UNITED STATES;

EID: 81155148130     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32834cd31d     Document Type: Review

References (120)

1. Rosen CJ. Vitamin D insufficiency. N Engl J Med 2011; 364:248-254.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206. (Pubitemid 37430058)
3. The sixth report of the Joint National Committee of prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572.
5. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153:154-183.
6. Joint National Committee for the Detection, Evaluation and Treatment of high blood pressure: The 1984 Report. Arch Intern Med 1984; 114:1045-1057.
7. Volhard F, Fahr T. Die brightsche Nierenkranbeit: Klinik, Pathologie und Atlas. Berlin: Springer; 1914.
8. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis.AmJ Med Sci 1939; 197:332-343.
9. Laragh J. Laraghs lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14:837-854. (Pubitemid 32862582)
10. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 1988; 78:636-640.
11. Kaplan NM. Treatment of hypertensive emergencies and urgencies. Heart Dis Stroke 1992; 1:373-378.
12. Potter JF. Malignant hypertension in the elderly. Q J Med 1995; 88:641-647.
13. McRae RPJ, Liebson PR. Hypertensive crisis. Med Clin North Am 1986; 70:749-767. (Pubitemid 16076100)
14. Vidt DG. Current concepts in treatment of hypertensive emergencies. Am Heart J 1986; 111:220-225. (Pubitemid 16136736)
15. Saguner AM, Dur S, Perrig M, et al. Risk factors promoting hypertensive crises: evidence from a longitudinal study. Am J Hypertens 2010; 23:775-780.
16. Zampaglione B, Pascale C, Marchisio M, et al. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension 1996; 27:144-147. (Pubitemid 26017693)
17. Gonzalez R, Morales E, Segura J, et al. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 2010; 25:3266-3272.
18. Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years experience in a multiracial population in England. J Hypertens 1994; 12:1297-1305. (Pubitemid 24348318)
19. Lane DA, Lip GY, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens 2009; 22:1199-1204.
20. Katz JN, Gore JM, Amin A, et al. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry. Am Heart J 2009; 158:599-606.
21. Tumlin JA, Dunbar LM, Oparil S, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 2000; 7:653-662. (Pubitemid 30390491)
22. Tisdale JE, Huang MB, Borzak S. Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Fam Pract 2004; 21:420-424. (Pubitemid 39162011)
23. Shea S, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992; 327:776-781.
24. Yu SH, Whitworth JA, Kincaid-Smith PS. Malignant hypertension: aetiology and outcome in 83 patients. Clin Exp Hypertens 1986; 8:1211-1230. (Pubitemid 16008211)
25. Milne FJ, James SH, Veriava Y. Malignant hypertension and its renal complications in black South Africans. S Afr Med J 1989; 76:164-167. (Pubitemid 19230696)
26. Espinel E, Tovar JL, Borrellas J, et al. Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension. J Clin Hypertens 2005; 7:11-15.
27. Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med 1985; 3:10-15. (Pubitemid 16135312)
28. Wallach R, Karp RB, Reves JG, et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol 1980; 46:559-565. (Pubitemid 10009807)
29. Funakoshi Y, Ichiki T, Ito K, et al. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 1999; 34:118-125. (Pubitemid 29325729)
30. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84:695-703. (Pubitemid 29157337)
31. Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am J Hypertens 2004; 17:852-860. (Pubitemid 39201104)
32. Van den Born BJ, Honnebier UP, Koopmans RP, et al. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005; 45:246-251. (Pubitemid 40179968)
33. Van den Born BJ, Lowenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 2011; 29:922-927.
34. Van den Born BJ, van der Hoeven NV, Groot E, et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008; 51:862-866. (Pubitemid 351654696)
35. Shantsila A, Dwivedi G, Shantsila E, et al. Persistent macrovascular and microvascular dysfunction in patients with malignant hypertension. Hypertension 2011; 57:490-496.
36. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest 2000; 118:214-227. (Pubitemid 30485512)
37. Garcia JYJ, Vidt DG. Current management of hypertensive emergencies. Drugs 1987; 34:263-278.
38. Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med 1990; 93:92-96.
39. Ziegler MG. Advances in the acute therapy of hypertension. Crit Care Med 1992; 20:1630-1631.
40. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Hypertension Society Consensus Conference. 3: Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997; 157:1245-1254.
41. Graves JW. Prevalence of blood pressure cuff sizes in a referral practice of consecutive adult hypertensives. Blood Press Monit 2001; 6:17-20. (Pubitemid 32269926)
42. Linfors EW, Feussner JR, Blessing CL, et al. Spurious hypertension in the obese patient. Effect of sphygmomanometer cuff size on prevalence of hypertension. Arch Intern Med 1984; 144:1482-1485. (Pubitemid 14087083)
43. Hickler RB. Hypertensive emergency: a useful diagnostic category. Am J Public Health 1988; 78:623-624.
44. Fromm RE, Varon J, Gibbs L. Congestive heart failure and pulmonary edema for the emergency physician. J Emerg Med 1995; 13:71-87.
45. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17-22. (Pubitemid 32064840)
46. Ferguson RK, Vlasses PH. Hypertensive emergencies and urgencies. JAMA 1986; 255:1607-1613. (Pubitemid 16167483)
47. Reuler JB, Magarian GJ. Hypertensive emergencies and urgencies: definition, recognition, and management. J Gen Intern Med 1988; 3:64-74.
48. Strandgaard S, Olesen J, Skinhoj E, et al. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973; 1:507-510.
49. Bannan LT, Beevers DG, Wright N. ABC of blood pressure reduction. Emergency reduction, hypertension in pregnancy, and hypertension in the elderly. Br Med J 1980; 281:1120-1122. (Pubitemid 10021421)
50. Bertel O, Marx BE, Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med 1987; 82:29-36.
51. Reed WG, Anderson RJ. Effects of rapid blood pressure reduction on cerebral blood flow. Am Heart J 1986; 111:226-228. (Pubitemid 16136737)
52. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131:1949-1962. (Pubitemid 46981658)
53. Varon J. The diagnosis and treatment of hypertensive crises. Postgrad Med 2009; 121:5-13.
54. Varon J, Marik PE. The management of hypertensive crisis. Crit Care 2003; 7:374-384.
55. Devlin JW, Dasta JF, Kleinschmidt K, et al. Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registry. Pharmacotherapy 2010; 30:1087-1096.
56. Brooks TW, Finch CK, Lobo BL, et al. Blood pressure management in acute hypertensive emergency. Am J Health Syst Pharm 2007; 64:2579-2582. (Pubitemid 350276299)
57. Pollack CV, Varon J, Garrison NA, et al. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 2009; 53:329-338.
58. Weder AB, Erickson S. Treatment of hypertension in the inpatient setting: use of intravenous labetalol and hydralazine. J Clin Hypertens 2010; 12:29-33.
59. Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 2011; 15:R157.
60. Hartmann A, Buttinger C, Rommel T, et al. Alteration of intracranial pressure, cerebral blood flow, autoregulation and carbondioxide-reactivity by hypotensive agents in baboons with intracranial hypertension. Neurochirurgia 1989; 32:37-43. (Pubitemid 19089362)
61. Kondo T, Brock M, Bach H. Effect of intra-arterial sodium nitroprusside on intracranial pressure and cerebral autoregulation. Jpn Heart J 1984; 25:231-237. (Pubitemid 14132585)
62. Griswold WR, Reznik V, Mendoza SA. Nitroprusside-induced intracranial hypertension [letter]. JAMA 1981; 246:2679-2680.
63. Anile C, Zanghi F, Bracali A, et al. Sodium nitroprusside and intracranial pressure. Acta Neurochirurgica 1981; 58:203-211. (Pubitemid 12238349)
64. Mann T, Cohn PF, Holman LB, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 1978; 57:732-738. (Pubitemid 8306850)
65. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306:1129-1135. (Pubitemid 12161335)
66. Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008; 107:1110-1121.
67. Spah F, Grosser KD. Treatment of hypertensive urgencies and emergencies with nitrendipine, nifedipine, and clonidine: effect on blood pressure and heart rate. J Cardiovasc Pharmacol 1988; 12 (Suppl 4):S154-S156.
68. Gonzalez-Carmona VM, Ibarra-Perez C, Jerjes-Sanchez C. Single-dose sublingual nifedipine as the only treatment in hypertensive urgencies and emergencies. Angiology 1991; 42:908-913.
69. Diker E, Erturk S, Akgun G. Is sublingual nifedipine administration superior to oral administration in the active treatment of hypertension? Angiology 1992; 43:477-481.
70. Komsuoglu SS, Komsuoglu B, Ozmenoglu M, et al. Oral nifedipine in the treatment of hypertensive crises in patients with hypertensive encephalopathy. Int J Cardiol 1992; 34:277-282.
71. Haft JI, Litterer WE. Chewing nifedipine to rapidly treat hypertension. Arch Intern Med 1984; 144:2357-2359. (Pubitemid 15214232)
72. Puri GD, Batra YK, Singh H. Efficacy of sublingual nifedipine in the relief of immediate postopertive hypertension. Indian J Med Res 1987; 86:624-628.
73. Wu SG, Lin SL, Shiao WY, et al. Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron 1993; 65:284-287.
74. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328-1331. (Pubitemid 26346933)
75. Strauss R, Gavras I, Vlahakos D, et al. Enalaprilat in hypertensive emergencies. J Clin Pharmacol 1986; 26:39-43. (Pubitemid 16164518)
76. DiPette DJ, Ferraro JC, Evans RR, et al. Enalaprilat, an intravenous angiotensin- converting enzyme inhibitor, in hypertensive crises. Clin Pharmacol Ther 1985; 38:199-204. (Pubitemid 16248173)
77. Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med 1991; 151:678-682.
78. Ceyhan B, Karaaslan Y, Caymaz O, et al. Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. Jpn J Pharmacol 1990; 52:189-193. (Pubitemid 20070260)
79. Hirschl MM, Binder M, Bur A, et al. Impact of the renin-angiotensin- aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises. J Hum Hypertens 1997; 11:177-183. (Pubitemid 27234678)
80. Bussmann WD, Kenedi P, von Mengden HJ, et al. Comparison of nitroglycerin with nifedipine in patients with hypertensive crisis or severe hypertension. Clin Investig 1992; 70:1085-1088.
81. Schroeder HA. Effects on hypertension of sulfhydryl and hydrazine compounds. J Clin Invest 1951; 30:672-673.
82. Shepherd AM, Ludden TM, McNay JL, et al. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 1980; 28:804-811. (Pubitemid 11213117)
83. OMalley K, Segal JL, Israili ZH, et al. Duration of hydralazine action in hypertension. Clin Pharmacol Ther 1975; 18:581-586.
84. Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther 1980; 28:769-778. (Pubitemid 11213113)
85. Ludden TM, Shepherd AM, McNay JL, et al. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther 1980; 28:736-742. (Pubitemid 11213108)
86. Moore-Jones D, Perry HM Jr. Radioautographic localization of hydralazine-1- C-14 in arterial walls. Proc Soc Exp Biol Med 1966; 122:576-579.
87. Halpern NA, Sladen RN, Goldberg JS, et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit Care Med 1990; 18:950-955. (Pubitemid 20311997)
88. Schillinger D. Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med 1987; 5:463-473. (Pubitemid 18048622)
89. Lambert CR, Hill JA, Feldman RL, et al. Effects of nicardipine on exercise- and pacing-induced myocardial ischemia in angina pectoris. Am J Cardiol 1987; 60:471-476. (Pubitemid 17138854)
90. Lambert CR, Hill JA, Nichols WW, et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985; 55:652-656. (Pubitemid 15148235)
91. Vincent JL, Berlot G, Preiser JC, et al. Intravenous nicardipine in the treatment of postoperative arterial hypertension. J Cardiothorac Vasc Anesth 1997; 11:160-164.
92. Lambert CR, Hill JA, Feldman RL, et al. Effects of nicardipine on left ventricular function and energetics in man. Int J Cardiol 1986; 10:237-250.
93. Rodriguez G, Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock 2006; 9:9-15.
94. Ericsson H, Tholander B, Regard HCG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharmaceut Sci 1999; 8:29-37. (Pubitemid 29117266)
95. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology 2002; 96:1086-1094. (Pubitemid 34462568)
96. Ericsson H, Fakt C, Jolin-Mellgard A, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol 1999; 47:531-538. (Pubitemid 29199725)
97. Segawa D, Sjoquist PO, Wang QD, et al. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts. Part II. J Cardiovasc Pharmacol 2002; 40:339-345. (Pubitemid 34971350)
98. Segawa D, Sjoquist PO, Wang QD, et al. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calciumantagonist clevidipine. J Cardiovasc Pharmacol 2000; 36:338-343. (Pubitemid 30660464)
99. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens 2002; 24:301-313. (Pubitemid 34602704)
100. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg 2007; 105:918-925. (Pubitemid 47479301)
101. Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg 2008; 107:59-67.
102. Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II: Haemodynamic effects of labetalol. Drugs 1984; 28 (Suppl 2):35-50. (Pubitemid 15192242)
103. Kanot J, Allonen H, Kleimola T, et al. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1981; 19:41-44. (Pubitemid 11160578)
104. Goldberg ME, Clark S, Joseph J, et al. Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J 1990; 119:446-450. (Pubitemid 20048401)
105. Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med 1994; 61:59-69. (Pubitemid 24053928)
106. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens 1985; 1:171-178.
107. Marx PG, Reid DS. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol 1979; 8:233S-238S. (Pubitemid 10180255)
108. Olsen KS, Svendsen LB, Larsen FS, et al. Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 1995; 75:51-54.
109. Rosei EA, Trust PM, Brown JJ. Intravenous labetalol in severe hypertension. Lancet 1975; 2:1093-1094.
110. Gray RJ. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker. Chest 1988; 93:398-403. (Pubitemid 18053085)
111. Lowenthal DT, Porter RS, Saris SD, et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 1985; 56:14F-18F. (Pubitemid 16216796)
112. Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 1986; 26 (Suppl A):A3-A14. (Pubitemid 16097793)
113. Balser JR, Martinez EA, Winters BD, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology 1998; 89:1052-1059. (Pubitemid 28516528)
114. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63:925-929. (Pubitemid 19105127)
115. Stumpf JL. Drug therapy of hypertensive crises. Clin Pharm 1988; 7:582-591.
116. Smerling A, Gersony WM. Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med 1990; 18:1288-1290. (Pubitemid 20377785)
117. Gray RJ, Bateman TM, Czer LS, et al. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol 1985; 56:49F-56F. (Pubitemid 16216801)
118. Gray RJ, Bateman TM, Czer LS, et al. Comparison of esmolol and nitroprusside for acute postcardiac surgical hypertension. Am J Cardiol 1987; 59:887-891. (Pubitemid 17061308)
119. Muzzi DA, Black S, Losasso TJ, et al. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg 1990; 70:68-71. (Pubitemid 20039981)
120. Mooss AN, Hilleman DE, Mohiuddin SM, et al. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother 1994; 28:701-703. (Pubitemid 24200918)